Bicara Therapeutics Inc. Operating Income (Loss) in USD from Q3 2023 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Bicara Therapeutics Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2023 to Q3 2025.
  • Bicara Therapeutics Inc. Operating Income (Loss) for the quarter ending September 30, 2025 was -$40.7M, a 97.2% decline year-over-year.
  • Bicara Therapeutics Inc. Operating Income (Loss) for the twelve months ending September 30, 2025 was -$141M.
  • Bicara Therapeutics Inc. annual Operating Income (Loss) for 2024 was -$82.4M, a 107% decline from 2023.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)

Bicara Therapeutics Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$141M -$40.7M -$20M -97.2% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-10
Q2 2025 -$121M -$32M -$12.3M -62.1% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-12
Q1 2025 -$109M -$41.8M -$26.4M -172% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-13
Q4 2024 -$82.4M -$26.6M Oct 1, 2024 Dec 31, 2024 10-K 2025-03-27
Q3 2024 -$20.6M -$11.1M -116% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-10
Q2 2024 -$19.8M Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-12
Q1 2024 -$15.4M Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-13
Q3 2023 -$9.53M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12

Bicara Therapeutics Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$82.4M -$42.5M -107% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-27
2023 -$39.9M Jan 1, 2023 Dec 31, 2023 10-K 2025-03-27
* An asterisk sign (*) next to the value indicates that the value is likely invalid.